持続血糖測定装置のアジア太平洋市場:構成要素別(センサー、送信機、受信機)、エンドユーザー別(病院、在宅医療、その他)、地域別

◆英語タイトル:Asia Pacific Continuous Glucose Monitoring Device Market By Component (Sensors, Transmitters, and Receivers) By End User (Hospitals, Homecare Settings and Other End Users) By Country, Industry Analysis and Forecast, 2020 - 2026
◆商品コード:KBV20JN107
◆発行会社(リサーチ会社):KBV Research
◆発行日:2020年4月
◆ページ数:81
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア
◆販売価格オプション(消費税別)
Single User(1名様利用)USD1,500 ⇒換算¥156,000見積依頼/購入/質問フォーム
Global License(法人利用)USD2,520 ⇒換算¥262,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKBV Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
KBV Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートは、持続血糖測定装置のアジア太平洋市場の現状と展望が網羅的に把握できるレポートです。持続血糖測定装置のアジア太平洋市場について、市場範囲・調査手法、市場動向、構成要素別(センサー、送信機、受信機)分析、エンドユーザー別(病院、在宅医療、その他)分析、地域別分析、企業概要などを把握し、将来性を考察しております。
・市場範囲・調査手法
・市場動向
・持続血糖測定装置のアジア太平洋市場:構成要素別(センサー、送信機、受信機)
・持続血糖測定装置のアジア太平洋市場:エンドユーザー別(病院、在宅医療、その他)
・持続血糖測定装置のアジア太平洋市場:地域別
・企業概要
【レポートの概要】

The Asia Pacific Continuous Glucose Monitoring Device Market would witness market growth of 13.7% CAGR during the forecast period (2020-2026).
As tested in many clinical studies, it has been found that diabetic patients with type 1 diabetes mellitus (T1DM) with continuous glucose monitoring have greater glycemic regulation relative to when using glucometer for daily blood glucose self-monitoring. The trend follows in children, as well as those who frequently use a CGM. The results in these children display better-glycosylated levels of hemoglobin (HbA1c) without an increased hyperglycemia frequency.
The latest CGM models have enabled the administration of electrochemical subcutaneous sensors based on glucose oxidase to measure glucose levels in the interstitial fluid. CGM apps may either show the patterns in blood glucose levels retrospectively by downloading the data or offer a real-time image of glucose levels via receiver displays. Many CGMs in real-time can provide patients, parents, or caregivers with an alert during current or pending glycemic visits to encourage timely blood glucose control.
Asia Pacific market is predicted to have the fastest growth over the projected period. Nearly 60 percent of the world’s diabetic population lives in the Asia Pacific region, according to the Asian Diabetes Prevention Initiative. The high prevalence of the disease has spurred global demand development in developed countries such as India and China. In addition, increasing healthcare spending, extensive business activity, and supportive regulatory policies will have a positive effect on the development of this region’s market.
Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson
Scope of the Study

Market Segmentation:
By Component
• Sensors
• Transmitters and
• Receivers

By End User
• Hospitals
• Homecare Settings and
• Other End Users

By Country
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled
• Abbott Laboratories
• Medtronic PLC
• F. Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• DexCom, Inc.
• Ypsomed AG
• Senseonics Holdings, Inc.
• GlySens, Incorporated
• A. Menarini Diagnostics Ltd. (The Menarini Group)
• Echo Therapeutics, Inc.
• Johnson and Johnson

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Continuous Glucose Monitoring Device Market, by Component
1.4.2 Asia Pacific Continuous Glucose Monitoring Device Market, by End User
1.4.3 Asia Pacific Continuous Glucose Monitoring Device Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Continuous Glucose Monitoring Device Market by Component
3.1 Asia Pacific Sensors Market by Country
3.2 Asia Pacific Transmitters Market by Country
3.3 Asia Pacific Receivers Market by Country
Chapter 4. Asia Pacific Continuous Glucose Monitoring Device Market by End-user
4.1 Asia Pacific Hospitals Continuous Glucose Monitoring Device Market by Country
4.2 Asia Pacific Homecare Settings Market by Country
4.3 Asia Pacific Other End Users Market by Country
Chapter 5. Asia Pacific Continuous Glucose Monitoring Device Market by Country
5.1 China Continuous Glucose Monitoring Device Market
5.1.1 China Continuous Glucose Monitoring Device Market by Component
5.1.2 China Continuous Glucose Monitoring Device Market by End-user
5.2 Japan Continuous Glucose Monitoring Device Market
5.2.1 Japan Continuous Glucose Monitoring Device Market by Component
5.2.2 Japan Continuous Glucose Monitoring Device Market by End-user
5.3 India Continuous Glucose Monitoring Device Market
5.3.1 India Continuous Glucose Monitoring Device Market by Component
5.3.2 India Continuous Glucose Monitoring Device Market by End-user
5.4 South Korea Continuous Glucose Monitoring Device Market
5.4.1 South Korea Continuous Glucose Monitoring Device Market by Component
5.4.2 South Korea Continuous Glucose Monitoring Device Market by End-user
5.5 Singapore Continuous Glucose Monitoring Device Market
5.5.1 Singapore Continuous Glucose Monitoring Device Market by Component
5.5.2 Singapore Continuous Glucose Monitoring Device Market by End-user
5.6 Malaysia Continuous Glucose Monitoring Device Market
5.6.1 Malaysia Continuous Glucose Monitoring Device Market by Component
5.6.2 Malaysia Continuous Glucose Monitoring Device Market by End-user
5.7 Rest of Asia Pacific Continuous Glucose Monitoring Device Market
5.7.1 Rest of Asia Pacific Continuous Glucose Monitoring Device Market by Component
5.7.2 Rest of Asia Pacific Continuous Glucose Monitoring Device Market by End-user
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Product Launches and Product Expansions:
6.2 Medtronic PLC
6.2.1 Company overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expenses
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Acquisition and Mergers:
6.2.5.3 Approvals:
6.3 F. Hoffmann-La Roche Ltd.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.3.5.2 Acquisition and Mergers:
6.4 Novo Nordisk A/S
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental & Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.5 DexCom, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Partnerships, Collaborations, and Agreements:
6.5.5.2 Approvals:
6.6 Ypsomed AG
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Senseonics Holdings, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.7.5.2 Approvals:
6.8 GlySens, Incorporated
6.8.1 Company Overview
6.8.2 Recent strategies and developments:
6.8.2.1 Approvals:
6.9 A. Menarini Diagnostics Ltd. (The Menarini Group)
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Partnerships, Collaborations, and Agreements:
6.1 Echo Therapeutics, Inc.
6.10.1 Company Overview
6.11 Johnson and Johnson
6.11.1 Company Overview
6.11.2 Financial Analysis
6.11.3 Segmental &Regional Analysis
6.11.4 Research & Development Expenses
6.11.5 Recent strategies and developments:
6.11.5.1 Approvals:



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[持続血糖測定装置のアジア太平洋市場:構成要素別(センサー、送信機、受信機)、エンドユーザー別(病院、在宅医療、その他)、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆